Accelerating The CMC Development Of Multi-Specific Biologics By Advanced Analytical Strategies And Technologies

Multi-specific biologics are gaining momentum as powerful next-generation therapies, yet their structural and functional complexity creates unique hurdles across CMC development. This webinar explores how advanced analytical strategies can be used to overcome those challenges and accelerate progress toward IND.

Drawing on more than a decade of hands-on experience, Dr. Tongdan Wang demonstrates how integrated, fit-for-purpose analytics—ranging from mispairing analysis and dual-target bioassays to high-resolution mass spectrometry—enable deeper molecule understanding and faster, more confident decision-making. The session highlights practical approaches for both symmetric and asymmetric bispecific antibodies, with real-world case studies in protease root-cause analysis and cell line optimization.

Attendees will also learn how automation, modular analytical toolboxes, and mechanism-of-action–reflective bioassays help reduce development risk while supporting regulatory-ready data packages.

Access the full webinar to see how modern analytics are reshaping multispecific biologics development.